Torisel (temsirolimus) / Pfizer 
Welcome,         Profile    Billing    Logout  
 366 Diseases   40 Trials   40 Trials   1659 News 


«12...89101112131415161718...2223»
  • ||||||||||  Torisel (temsirolimus) / Pfizer
    Trial primary completion date:  Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma (clinicaltrials.gov) -  Nov 22, 2017   
    P4,  N=90, Active, not recruiting, 
    Our collective results demonstrate that Reolysin possesses CXCL10-driven anti-angiogenic activity in sarcoma models, which can be harnessed to enhance the anticancer activity of temsirolimus and other agents that target the tumor vasculature. Trial primary completion date: May 2016 --> Nov 2015
  • ||||||||||  Votrient (pazopanib) / Novartis, BeiGene
    Enrollment change, Trial termination, Metastases:  Second Line Sorafenib After Pazopanib in Patients With RCC (clinicaltrials.gov) -  Nov 22, 2017   
    P2,  N=16, Terminated, 
    Trial primary completion date: May 2016 --> Nov 2015 N=44 --> 16 | Recruiting --> Terminated; availability of new and more promising therapeutic agents than expected in the experimentation in question
  • ||||||||||  ganetespib (ADX-1612) / Aldeyra
    Trial primary completion date, Combination therapy, Metastases:  SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) (clinicaltrials.gov) -  Nov 14, 2017   
    P1/2,  N=38, Active, not recruiting, 
    N=44 --> 16 | Recruiting --> Terminated; availability of new and more promising therapeutic agents than expected in the experimentation in question Trial primary completion date: Dec 2017 --> Apr 2018
  • ||||||||||  Trial initiation date:  NCT Neuro Master Match - N (clinicaltrials.gov) -  Nov 1, 2017   
    P1/2,  N=350, Not yet recruiting, 
    Trial primary completion date: Dec 2017 --> Apr 2018 Initiation date: Jul 2017 --> Jan 2018
  • ||||||||||  everolimus / Generic mfg., Torisel (temsirolimus) / Pfizer
    Biomarker, Review, Journal:  Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. (Pubmed Central) -  Sep 21, 2017   
    Challenges to the therapeutic effectiveness of some PI3K inhibitors include the absence of reliable and effective biomarkers, their limited efficacy as single agents, insufficient development of rational therapeutic combinations, the use of schedules with a variety of off-target effects, and suboptimal therapeutic exposures. Therefore, with regard to PI3K inhibitors currently in late-stage clinical trials, the identification of appropriate biomarkers of efficacy and the development of optimal combination regimens and dosing schedules are likely to be important for graduation into clinical practice.
  • ||||||||||  perifosine (D21266) / AEterna Zentaris, Torisel (temsirolimus) / Pfizer
    Journal:  A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. (Pubmed Central) -  Sep 16, 2017   
    Therefore, with regard to PI3K inhibitors currently in late-stage clinical trials, the identification of appropriate biomarkers of efficacy and the development of optimal combination regimens and dosing schedules are likely to be important for graduation into clinical practice. The combination of these AKT and mTOR inhibitors was safe and feasible in patients with recurrent/refractory pediatric solid tumors.
  • ||||||||||  Votrient (pazopanib) / Novartis, Torisel (temsirolimus) / Pfizer
    Enrollment closed, Enrollment change, Trial primary completion date:  Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) (clinicaltrials.gov) -  Sep 12, 2017   
    P2,  N=69, Active, not recruiting, 
    Further evaluation of biomarkers in a larger cohort of patients might identify those most likely to respond to this chemoimmunotherapeutic regimen. Recruiting --> Active, not recruiting | N=90 --> 69 | Trial primary completion date: Oct 2018 --> Oct 2019
  • ||||||||||  Torisel (temsirolimus) / Pfizer, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Trial completion, Enrollment change, Trial primary completion date:  BERT: Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma (clinicaltrials.gov) -  Sep 11, 2017   
    P1/2,  N=39, Completed, 
    Recruiting --> Active, not recruiting | N=90 --> 69 | Trial primary completion date: Oct 2018 --> Oct 2019 Active, not recruiting --> Completed | N=72 --> 39 | Trial primary completion date: Mar 2016 --> Sep 2017
  • ||||||||||  Votrient (pazopanib) / Novartis, BeiGene
    Enrollment open, Trial initiation date, Trial primary completion date, Metastases:  Second Line Sorafenib After Pazopanib in Patients With RCC (clinicaltrials.gov) -  Aug 28, 2017   
    P2,  N=44, Recruiting, 
    Active, not recruiting --> Completed | N=72 --> 39 | Trial primary completion date: Mar 2016 --> Sep 2017 Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Sep 2016 | Trial primary completion date: Apr 2016 --> Dec 2017
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date:  Personalized Targeted Inhibitors Treatment in Renal Cell Cancer (clinicaltrials.gov) -  Aug 3, 2017   
    P2,  N=4, Terminated, 
    Initiation date: Mar 2014 --> Aug 2014 N=100 --> 4 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Jul 2017; Loss of laboratory performing molecular analysis
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Enrollment closed, Trial primary completion date, Metastases:  Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) (clinicaltrials.gov) -  Jun 27, 2017   
    P1/2,  N=49, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Apr 2018
  • ||||||||||  Torisel (temsirolimus) / Pfizer
    Trial primary completion date:  Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (clinicaltrials.gov) -  Jun 26, 2017   
    P3,  N=253, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Apr 2018 Trial primary completion date: Jun 2017 --> Dec 2018
  • ||||||||||  Torisel (temsirolimus) / Pfizer
    Trial primary completion date, Metastases:  Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Jun 21, 2017   
    P2,  N=27, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jun 2015 Trial primary completion date: Sep 2017 --> May 2016
  • ||||||||||  Torisel (temsirolimus) / Pfizer
    Trial completion, Trial primary completion date, Metastases:  Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Jun 16, 2017   
    P1,  N=25, Completed, 
    Trial primary completion date: Sep 2017 --> May 2016 Active, not recruiting --> Completed | Trial primary completion date: Apr 2012 --> Sep 2012
  • ||||||||||  Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
    Enrollment closed, Trial primary completion date:  Doxil, Bevacizumab and Temsirolimus Trial (clinicaltrials.gov) -  May 31, 2017   
    P1,  N=200, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Apr 2012 --> Sep 2012 Completed --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Aug 2018
  • ||||||||||  Torisel (temsirolimus) / Pfizer
    Biomarker, Trial primary completion date:  FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib (clinicaltrials.gov) -  May 30, 2017   
    P1,  N=5, Active, not recruiting, 
    Completed --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Aug 2018 Trial primary completion date: Jun 2018 --> Jun 2019
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD), Torisel (temsirolimus) / Pfizer
    Trial primary completion date, Epigenetic controller, Metastases:  Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer (clinicaltrials.gov) -  May 22, 2017   
    P1,  N=249, Active, not recruiting, 
    Response rate and median PFS suggest clinical activity for this combination strategy in previously treated ccRCC. Trial primary completion date: Mar 2018 --> Mar 2019
  • ||||||||||  New P1/2 trial:  NCT Neuro Master Match - N (clinicaltrials.gov) -  May 18, 2017   
    P1/2,  N=350, Not yet recruiting, 
  • ||||||||||  Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
    Journal:  The clinical management of inoperable endometrial carcinoma. (Pubmed Central) -  May 5, 2017   
    Given the paucity of inoperable disease, randomized clinical data is lacking in this specific patient population. Management decisions regarding radiation therapy or systemic therapy are largely guided by the existing data in the setting of recurrence or second-line treatment, adjuvant therapy following optimal debulking, or in patients who are considered inoperable due to medical comorbidities rather than the extent of their disease.
  • ||||||||||  Torisel (temsirolimus) / Pfizer
    Trial primary completion date, Metastases:  Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) (clinicaltrials.gov) -  Apr 26, 2017   
    P1/2,  N=48, Active, not recruiting, 
    Management decisions regarding radiation therapy or systemic therapy are largely guided by the existing data in the setting of recurrence or second-line treatment, adjuvant therapy following optimal debulking, or in patients who are considered inoperable due to medical comorbidities rather than the extent of their disease. Trial primary completion date: Nov 2017 --> Nov 2018